Testosterone Enanthate Compounded vs Branded: A Clinical Comparison

What Is Testosterone Enanthate and Why Does Formulation Matter?

Testosterone enanthate is a long-acting testosterone ester in which a C-17 enanthate side chain slows absorption from the injection depot, producing a half-life of roughly 4.5 days. The FDA-approved reference product, Delatestryl, has been on the US market since 1953 and carries a defined manufacturing standard under current Good Manufacturing Practice (cGMP) regulations enforced by the FDA [1]. Compounded versions are prepared by 503A retail pharmacies (patient-specific) or 503B outsourcing facilities (larger batch) under US Pharmacopeia standards, but without the same post-market surveillance requirements [2].

Formulation matters for three concrete reasons. First, potency variation in compounded injectables has been documented: a 2012 FDA laboratory analysis of compounded sterile preparations found that roughly 25% of samples tested outside acceptable potency limits [3]. Second, the oil vehicle and preservative differ across compounders, which changes injection tolerability and shelf stability. Third, Schedule III controlled-substance rules require specific DEA registration for compounding pharmacies, adding a compliance layer that not every telehealth supply chain handles uniformly [4].

The 503A vs 503B Distinction

503A pharmacies compound for individual prescriptions. They may not sell anticipatory stock and are state-board regulated with limited federal inspection. 503B outsourcing facilities register with the FDA, submit to biennial inspections, and may distribute larger volumes to clinics without a patient-specific prescription [2]. When a telehealth platform ships compounded testosterone enanthate, the legal pathway matters. Prescribers should confirm their pharmacy holds the correct registration.

Vehicle and Concentration Differences

Delatestryl uses sesame oil with chlorobutanol as preservative at a fixed 200 mg/mL concentration. Compounders frequently offer 100 mg/mL, 200 mg/mL, 250 mg/mL, or even 400 mg/mL in cottonseed, grapeseed, or MCT oil. Higher concentration formulations reduce injection volume, which some patients prefer for subcutaneous administration, but the FDA has not evaluated these concentrations for safety or tolerability [1].

Clinical Evidence: What the T-Trials Tell Us

The T-Trials (Testosterone Trials) published in NEJM in 2016 remain the most rigorous randomized controlled dataset on testosterone therapy in older men. The coordinated network of seven trials enrolled 788 men aged 65 years or older with a serum testosterone below 275 ng/dL [5].

Primary Findings Across the Seven Sub-Trials

The sexual function trial showed a statistically significant improvement in the PDAS (Patient Desire and Activity Scale) score with testosterone gel (mean difference 0.58 points, 95% CI 0.37 to 0.78, P<0.001) compared with placebo [5]. The physical function trial demonstrated a mean increase of 29.4 meters in 6-minute walk distance in the testosterone arm versus 14.5 meters in placebo (P = 0.007) [5]. The vitality trial showed testosterone improved scores on the FACIT-Fatigue scale by a mean of 2.4 points more than placebo (P = 0.002) [5].

The T-Trials used a transdermal gel rather than testosterone enanthate injection, but the pharmacokinetic target was identical: sustained total testosterone between 500 and 1000 ng/dL. The Endocrine Society 2018 guideline explicitly states that the clinical benefits observed across testosterone formulations are driven by testosterone levels achieved, not by the delivery vehicle, making T-Trials data applicable to injectable enanthate therapy when similar trough levels are maintained [6].

What the T-Trials Did Not Show

The bone density sub-trial did show increased volumetric bone mineral density at the spine (P<0.001) and the hip (P = 0.004), but the cardiovascular trial found a non-significant trend toward more coronary artery plaque in the testosterone arm [5]. The Endocrine Society guideline advises against initiating testosterone therapy in men with recent myocardial infarction, stroke, or poorly controlled heart failure until more outcome data are available [6].

Regulatory and Safety Differences

FDA Oversight of Branded Testosterone Enanthate

Delatestryl is subject to the full NDA (New Drug Application) framework. The manufacturer must demonstrate batch-to-batch consistency, submit adverse event reports under MedWatch, and follow FDA-mandated label language including a black-box warning about secondary exposure risks and cardiovascular events [1]. The FDA's label for testosterone products requires a Risk Evaluation and Mitigation Strategy (REMS) program called the Testosterone REMS, which requires providers to counsel patients on polycythemia, sleep apnea, and cardiovascular risk before prescribing [1].

Compounded Testosterone Enanthate: Where Oversight Gaps Exist

The FDA's 2020 guidance on compounding of biologically identical hormones specifically notes that compounding of a commercially available product is generally not permissible under 503A unless the prescriber documents a specific patient need that the commercial product cannot meet (for example, allergy to sesame oil) [2]. Clinically, a documented allergy to sesame oil or chlorobutanol is the clearest legitimate indication for a compounded formulation [4].

Potency variation remains the most clinically consequential gap. A study published in the Journal of Clinical Endocrinology and Metabolism found that 34 of 103 compounded testosterone products tested outside the USP-specified 90 to 110% potency range, with some samples containing as little as 74% of labeled concentration [7]. Under-potent product leads to undertreated hypogonadism. Over-potent product risks polycythemia and cardiovascular strain.

The FDA's Current Enforcement Posture

The FDA issued a safety communication in 2015 adding a label update to all FDA-approved testosterone products warning of potential increases in cardiovascular risk [1]. Compounded products are not subject to that mandatory labeling, meaning patients receiving compounded testosterone enanthate may not receive the same written risk disclosures [2]. Prescribers ordering compounded product carry additional informed-consent responsibility.

Dosing Protocols: Branded vs Compounded

Standard Dosing with Delatestryl

The FDA-approved labeling for Delatestryl specifies 50 to 400 mg intramuscularly every 2 to 4 weeks for male hypogonadism [1]. In clinical practice, most endocrinologists now use shorter intervals to reduce peak-to-trough variability. The Endocrine Society 2018 guideline recommends 75 to 100 mg IM weekly or 150 to 200 mg IM every 2 weeks, targeting a trough total testosterone of 400 to 700 ng/dL drawn before the next scheduled injection [6].

A serum trough drawn at week 6 (after steady-state is reached) guides dose adjustment. If trough falls below 350 ng/dL on a weekly protocol, increasing dose by 25 mg weekly is a reasonable first step. If trough exceeds 700 ng/dL, reducing dose or extending interval reduces polycythemia risk [6].

Subcutaneous Administration with Compounded Formulations

Subcutaneous (SC) testosterone enanthate injection has grown in telehealth practice because it is easier for patients to self-administer. A prospective study by Winters et al. (2020) in 40 men compared SC testosterone cypionate (a structurally similar ester) at 50 mg twice weekly versus IM at 100 mg weekly and found comparable trough levels and tolerability, with lower peak-to-trough ratios in the SC arm [8]. Compounded higher-concentration products (250 mg/mL) reduce the volume injected per SC dose to 0.2 to 0.4 mL, which is more practical for SC sites. Branded Delatestryl at 200 mg/mL requires 0.375 to 0.5 mL for a 75 to 100 mg dose, which is within SC tolerance, but clinicians should note this use is off-label.

Monitoring Schedule

The Endocrine Society recommends measuring total testosterone, hematocrit, and PSA (in men over 40 or with prostate risk) at 3 months after initiation and then at 6 and 12 months [6]. Hematocrit above 54% warrants dose reduction or temporary discontinuation regardless of formulation [6]. Patients on compounded product at non-standard concentrations should be reminded that the number on the syringe (in mL) must be recalculated for each concentration change; medication errors from concentration mismatches have been reported to the FDA MedWatch system [3].

Cost and Access

Branded Delatestryl without insurance costs approximately $140, $180 for a 5 mL multi-dose vial (1,000 mg total), equating to roughly $14, $18 per 100 mg dose. Compounded testosterone enanthate from a 503B facility typically runs $30, $60 for a 10 mL vial at 200 mg/mL (2,000 mg total), or $1.50, $3.00 per 100 mg dose. The 40 to 70% cost savings is real and clinically relevant for uninsured or underinsured patients.

Insurance Coverage Patterns

Most commercial insurance plans cover Delatestryl or its generic equivalents (generic testosterone enanthate 200 mg/mL is available from several manufacturers including Pfizer/Pharmacia and West-Ward) with a Tier 2 or Tier 3 co-pay averaging $20, $60 per vial. Compounded products are generally not covered because they lack an NDC (National Drug Code) that maps to an approved formulary entry. Medicare Part D does not cover compounded Schedule III controlled substances from 503A pharmacies.

Generic Branded vs Compounded

Generic FDA-approved testosterone enanthate 200 mg/mL is often the most cost-effective option that retains cGMP manufacturing assurance. For patients who do not require a non-standard concentration and have no documented excipient allergy, generic branded product at $15, $25 per vial (with GoodRx-type discount programs) closes most of the cost gap with compounded versions while preserving regulatory oversight.

Who Should Use Compounded Testosterone Enanthate?

The Endocrine Society and the FDA both acknowledge that compounding serves a legitimate purpose when the commercial product does not meet a specific patient need [2, 6]. Clinically appropriate indications for compounded testosterone enanthate include:

• Documented allergy to sesame oil or chlorobutanol present in Delatestryl, where an alternative oil vehicle is required.
• Need for a non-standard concentration (for example, 100 mg/mL for low-dose SC protocols in patients requiring precise titration).
• Commercial supply shortage, which the FDA recognized during the COVID-19-era drug shortage list period.
• Cost barrier after exhausting generic branded options, with prescriber documentation of medical necessity.

For all other patients, current evidence and FDA guidance favor the FDA-approved product or its generic equivalents. A prescriber who routinely orders compounded testosterone enanthate for cost convenience alone operates in a regulatory gray area and assumes greater liability if an adverse event related to potency variation occurs [2, 4].

Safety Monitoring: Shared Concerns Across Formulations

Both branded and compounded testosterone enanthate carry the same biological risks because both deliver testosterone to physiological targets. The 2010 Testosterone in Older Men with Mobility Limitations (TOM) trial was stopped early after interim analysis showed a higher rate of cardiovascular adverse events in the testosterone arm (23 events, 23.1%) versus placebo (5 events, 5.0%) in frail older men [9]. The FDA cited the TOM trial when adding the cardiovascular warning to testosterone labeling in 2015 [1].

Polycythemia

Testosterone stimulates erythropoiesis via erythropoietin upregulation in the kidney. The T-Trials reported a hematocrit increase averaging 3.0 percentage points from baseline in the testosterone arm at 12 months [5]. Men with baseline hematocrit above 48% or with sleep apnea carry higher polycythemia risk and require more frequent monitoring: every 3 months for the first year [6].

Prostate Safety

A 2023 systematic review published in JAMA Oncology (N = 5,647 men across 11 RCTs) found no statistically significant increase in prostate cancer incidence with testosterone therapy over 12 to 24 months of follow-up (RR 1.07, 95% CI 0.65 to 1.76) [10]. The Endocrine Society continues to recommend PSA monitoring at 3 and 12 months, with urology referral for a rise of more than 1.4 ng/mL above baseline within the first 12 months [6].

Injection-Site Reactions

Oil vehicle type influences local tolerability. Sesame oil (Delatestryl) and cottonseed oil (common in compounded products) have different viscosities, which affects injection force and the rate of rare oil embolism events. Grapeseed and MCT oil formulations available from compounders have lower viscosity and anecdotally better SC tolerability, though no randomized trial has directly compared vehicle-specific injection-site adverse event rates in testosterone enanthate formulations [8].

Prescriber Decision Framework

Selecting between branded and compounded testosterone enanthate requires balancing regulatory, clinical, and economic variables for each patient. The following four-question sequence guides the decision:

1. Does the patient have an allergy or intolerance to any excipient in Delatestryl? If yes, a compounded formulation with an alternative vehicle is warranted.
2. Does the patient require a concentration not available in the FDA-approved product? If yes, 503B compounding is appropriate with documented rationale.
3. Is the FDA-approved product available and covered by the patient's insurance? If yes, use the approved product.
4. If the patient is uninsured and cost is prohibitive, has a generic branded product been evaluated via discount programs? If a generic remains unaffordable after GoodRx or similar review, compounding from a 503B-registered facility with documented batch testing is an acceptable alternative.

This framework aligns with the FDA's compounding guidance and the Endocrine Society's 2018 clinical practice guideline, which states: "We recommend using testosterone formulations that are approved by national regulatory agencies rather than compounded testosterone products due to uncertainty about their purity, potency, and pharmacokinetics." [6]

Telehealth-Specific Considerations

Telehealth TRT programs frequently default to compounded testosterone enanthate or cypionate because the supply chain is simpler and cost differentials improve patient retention. The FDA's 2023 proposed rule on pharmacy compounding would, if finalized, restrict 503A pharmacies from compounding drugs that are copies of commercially available products without a patient-specific clinical rationale on file [2]. Prescribers operating in telehealth should document the clinical rationale for compounding in each chart note, not as a blanket policy.

Remote monitoring is fully adequate for testosterone enanthate therapy. A dried blood spot (DBS) test for total testosterone, hematocrit, and PSA has been validated against venipuncture in TRT patients in a study published in the Journal of Clinical Endocrinology and Metabolism, with a mean total testosterone correlation coefficient of r = 0.94 [11]. This validation supports home-based monitoring for telehealth TRT patients who cannot access a local lab.